P863 Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients
L Ramos Lopez,R Ramos-Díaz,F Benítez-Zafra,A Morant-Domínguez,B Vera-Santana,I Mourani-Padrón,I Alonso-Abreu,M Carrillo-Palau,C Reygosa,J S Medina-Chico,F Gutierrez-Nicolás,J Nazco-Casariego,M Hernández-Guerra
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0993
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Therapeutic drug monitoring (TDM) serves as a valuable tool for improving efficacy and reducing rates of drug toxicity .However, the utility of TDM with non-anti-TNF agents (such as Ustekinumab-UST) is less well defined, although it may be useful in optimizing UST posology and improving efficacy. In this study, we aimed to evaluate clinical outcomes and UST plasmatic concentration in real-world IBD patients. Methods A prospective study was conducted including IBD patients who initiated UST therapy between August 2020 and June 2023. Clinical outcomes were prospectively collected (clinical remission as Harvey-Bradshaw Index (HBI) <4 or partial Mayo score (pMS)≤1; biochemical remission as fecal calprotectin (FC)<150 g/kg); physician global assessment (PGA) (active/ not active) and patient-reported outcome (IBDQ-9)) and UST plasmatic concentration was assessed by ELISA every 8 weeks for 12 months. The need for drug escalation, surgery, hospitalization, or discontinuation of treatment at the end of the follow-up (September 2023) was recorded. Results A total of 91 patients were included (population described in Table 1). After a median follow-up of 12 (9.6-10.7) months, clinical remission was observed in 90.4% of CD and 66.6 % of UC patients, 52.7% presented biochemical remission and 61.5% of IBD patients were inactive by PGA. 81% of patients showed a good quality of life as measured by IBDQ-9 >60 points. 9.9% needed IBD hospitalization and only 1 (1.09%) patient required IBD surgery. UST-dose escalation was indicated for 33% of patients, mainly in UC patients (UC 46.1% vs CD 28.1%; p=0.42). Treatment discontinuation was required in 13.2% (12/91) of patients after a median follow-up of 15 (14.8-19) months, due to loss of response in 66.6% of these patients (Figure 1A). The mean UST concentration at induction (8 weeks) was significantly higher than at maintenance (16 weeks) (9.2 (7.7-10.7) μg/ml vs 4.8 (3.9-5.7); p>0.0001); no differences in UST concentration were found during the maintenance treatment (Figure 1B). UST concentration was not related to age, sex, body mass index, type of IBD, or previous exposure to biological agents. In multivariate analysis, UST concentration >7 μg/ml in maintenance (16 weeks) showed an independent predictive value for IBD hospitalization (OR 7.6, 95% CI 2.5-23.1) and UST-dose escalation (OR 4.1, 95% CI 1.4-11.9) in the next 12 months. Conclusion Ustekinumab (UST) is an effective treatment, bringing about clinical remission and an enhanced quality of life for individuals with inflammatory bowel disease (IBD). In our prospective cohort, UST concentration at maintenance serves as a predictive indicator of IBD outcome.
gastroenterology & hepatology